Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-Kids: Lerodalcibep in Pediatric Patients With HeFH
NCT07102511Phase 3Enrolling by invitation
- Sponsor
- LIB Therapeutics
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Lerodalcibep with Placebo (2 arms). Primary endpoint: Low Density Lipoprotein cholesterol reduction at 24 weeks. Started Jul 2026; status: enrolling by invitation.
02
Drugs
lerodalcibep
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT07102511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102511.